You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Gilead to buy Immunomedics for $21bn

Gilead Sciences has announced plans to acquire Immunomedics in a deal valued at $21 billion.